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doi:10.101Incidence of Viral and Fungal Infections following
Busulfan-Based Reduced-Intensity versus
Myeloablative Conditioning in Pediatric Allogeneic
Stem Cell Transplantation Recipients
Prakash Satwani,1 Leah Baldinger,1 Jason Freedman,1 Judith S. Jacobson,2 Jon Guerra,1
Carmella van de Ven,1 Erin Morris,1 James Garvin,1 Diane George,1 M. Brigid Bradley,1
Monica Bhatia,1 Bradford Tallamy,1 Joseph Schwartz,3 Zhezhen Jin,4 Mitchell S. Cairo1,3,5Reductions in the duration and nadir of neutropenia have translated into a significant decrease in bacteremia
in adult recipients of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning
(RIC) during the first 30 days after transplantation. It remains to be determined whether RIC allo-SCT
also will result in a decrease in systemic viral infections (SVIs) and invasive fungal infections (IFIs), which
are more dependent on alterations in cellular immunity. We compared the incidence of SVIs and IFIs in chil-
dren receiving busulfan-based RIC allo-SCTand in children receiving myeloablative conditioning (MAC) allo-
SCT for various malignant and nonmalignant diseases. Allo-SCTrecipients at risk for cytomegalovirus (CMV)
received ganciclovir/foscarnet, and most of the patients received antifungal prophylaxis with liposomal am-
photericin B until day1100. Eighty-six patients (median age, 7.5 years; 70% with malignant disease, 30% with
nonmalignant disease; 80% average risk, 20% poor risk) were evaluated. The probability of developing grade
II-IV acute graft-versus-host disease (aGVHD) was 29.1% (95% confidence interval [CI]516.7%-41.6%) in
RIC allo-SCT versus 40.3% (95% CI523.9%-56.6%) in MAC allo-SCT (P5.23), and that of chronic GVHD
(cGVHD) was 28.9% (95% CI514.7%-43.0%) in RIC allo-SCT versus 28.4% (95% CI510.5%-46.3%) in
MAC allo-SCT (P5.73). The overall probability of developing an SVI was 58%, and that of developing an
IFI was 15%. These probabilities did not differ significantly by conditioning intensity. In a multivariate Cox re-
gression model, the following were identified as independent risk factors for invasive fungal infection: older
age (hazard ratio [HR]51.3; 95% CI51.1-1.6; P5\ .01), poor risk status (HR56.5; 95% CI 51.1-37.4;
P5.03), and CMV-positive recipient (high vs low CMV risk group, HR526.7; 95% CI53.4-210.8; P5\.01).
Overall infection-related mortality was only 1.1% (1/86) for SVIs and 2.3% (2/86) for IFIs. Our data indicate
that RIC allo-SCT does not carry a lower risk of SVIs and IFIs than MAC allo-SCT in pediatric recipients.
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Allogeneic hematopoietic stem cell transplantation
(allo-SCT) as a treatment option for hematologic ma-
lignancies has long been based on the assumption that
myeloablative (MA) doses of cytotoxic therapy are re-
quired for both disease eradication and host immuno-
suppression. But the last decade has seen a paradigm
shift toward the curative potential of a graft-versus-
leukemia (GVL) or graft-versus-tumor (GVT) effect
[1]. The concept behind reduced-intensity condition-
ing (RIC) allo-SCT is that instead of eradicating tu-
mors through intensive/toxic chemoradiation, tumor
eradication is done using the SCT donor’s immune
cells, relying on allogeneic GVT effects [2]. In patients
with nonmalignant disease, the aim of RIC allo-SCT is
to create an immunologic platform of host and donor1587
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tation immunosuppression.
Data on RIC allo-SCT in pediatric recipients are
limited [3,4]. We previously demonstrated the feasibil-
ity and safety of the RIC allo-SCT approach in chil-
dren with malignant and nonmalignant diseases [5,6].
We also demonstrated the safety of RIC allo-SCT
and consolidation with gemtuzumab ozagamicin in
children with average-risk acute myelogenous leuke-
mia (AML) [7].
Following myeloablative conditioning (MAC) allo-
SCT, patients experience a period of profound neutro-
penia, severe mucositis, and immunodeficiency that can
lead to serious infectious complications that may result
in significant morbidity and mortality. Theoretically,
RIC allo-SCT could carry a lower risk of opportunistic
infections. The potential mechanism(s) that may be
responsible for this hypothetical reduced infectious
morbidity following RIC allo-SCT includes shorter
duration of severe neutropenia, lower grade of mucosi-
tis, enhanced immune reconstitution, decreased rate of
severe acute graft-versus-host disease (aGVHD), and
less use of immunosuppression compared with MAC
allo-SCT [8,9]. Junghanss et al. [10] reported a signifi-
cantly reduced risk of bacterial infection during the first
100 days posttransplantation in adult recipients of RIC
allo-SCT. But, because of intense pretransplantation
and/or posttransplantation immunosuppression, pa-
tients receiving RIC regimens actually may be at greater
risk for systemic viral infections (SVIs) and invasive
fungal infections (IFIs). Identified risk factors for devel-
oping SVIs after RIC allo-SCT include lymphopenia,
cytomegalovirus (CMV), serologic status of the donor
and recipient, in vivo T cell depletion using antithymo-
cyte globulin (ATG) or alemtuzumab, and ex vivo T cell
depletion [11,12].
Adenovirus (ADV) and CMV are serious causes of
morbidity and mortality in patients undergoing allo-
SCT. CMV infection is one of the most devastating
infectious complications associated with allo-SCT.
CMV reactivation occurs in 60%-80% of allo-SCT
recipients who are CMV-seropositive and/or have
a seropositive donor and do not receive CMV prophy-
laxis and/or preemptive therapy [13]. The rate of ADV
infection in allo-SCT recipients is 5%-27%, and mor-
tality ranges from 8% to 54%. The mortality rate is
higher in patients with ADV pneumonia (73%) and
disseminated disease (61%) [14]. The rate of ADV
infection is 4%-6% in adult allo-SCT recipients, but
as high as 47% in pediatric allo-SCT recipients [15].
IFI is another leading cause of infectious mortality
following allo-SCT (10%-20%) [16]. The incidence of
IFIs has increased from 5.7% to 11.2% over the last
decade [17]. Risk factors for developing an IFI include
prolonged neutropenia, unrelated or mismatched
donor source, and aGVHD or chronic GVHD
(cGVHD) and its treatment. Adult RIC allo-SCTand MAC allo-SCT recipients have equivalent risks
for aspergillosis; however, there was a trend toward
increased 1-year survival in RIC allo-SCT recipients
following invasive aspergillosis [18].
There have been a few prospective and retrospec-
tive studies in adults regarding the incidence and
outcome of SVIs and IFIs following RIC allo-SCT
[10-12]. Some of those studies have suggested that
RIC allo-SCT is associated with increased risk of
CMV, Epstein-Barr virus (EBV), ADV, and IFIs
[14-18]. Children undergoing allo-SCT may be at
greater risk for primary viral infections; however, there
is a paucity of data on SVIs and IFIs in children follow-
ing RIC and MAC allo-SCT. In the present study, we
compared the incidence and risk factors for SVIs and
IFIs following busulfan-based RIC allo-SCT versus
MAC allo-SCT.PATIENTS AND METHODS
Patients
Patients included consecutive children and adoles-
cents who underwent busulfan (Bu)-based RIC allo-
SCT at the Morgan Stanley Children’s Hospital of
New York-Presbyterian, between January 2001 and
December 2007. Indications for transplantation in-
cluded various malignant and nonmalignant condi-
tions. Allogeneic stem cell sources included bone
marrow (BM), peripheral blood stem cells (PBSCs),
and umbilical cord blood (UCB). Poor-risk malignant
patients were defined as those with chemoresistant ma-
lignant disease, in third complete remission (CR3) or
greater, induction failure, progressive disease, and/or
receiving a second allograft. All other patients with ma-
lignant and nonmalignant diseases were defined as av-
erage risk. All patients were on clinical protocols for
allo-SCT approved by the Institutional Review Board
at Columbia University Medical Center, and all re-
search protocols were in compliance with the Declara-
tion of Helsinki.Conditioning Regimens
The conditioning regimens were protocol-driven
and disease-specific. Patients with comorbid features
before undergoing allo-SCT were prioritized for
RIC regimens; prioritization of the remaining patients
was protocol-driven and disease-specific. All patients
without comorbid features were offered MAC. The
RIC arm included patients who received Bu (6.4-8
mg/kg), fludarabine (Flu; 150-180 mg/m2) 6 rabbit
antithymocyte globulin (ATG; 8 mg/kg) or Bu (12.8-
16 mg/kg), and Flu (150-180 mg/m2) 6 alemtuzumab
(54 mg/m2). The MAC arm included patients who
received Bu (12.8-16 mg/kg), cyclophosphamide (Cy)
(120-200 mg/kg) 6 rabbit ATG (8 mg/kg) or Bu
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rabbit ATG (8 mg/kg). Forty-four children received
rabbit ATG (MAC allo-SCT, n521; RIC allo-SCT,
n523), and 16 children received alemtuzumab
(54 mg/m2) (MAC allo-SCT, n50; RIC allo-SCT,
n516). Patients with acute lymphoblastic leukemia
(ALL) were excluded because they were treated with
a total body irradiation (TBI)-based MAC regimen.
GVHD Prophylaxis and Grading
aGVHD prophylaxis in the majority of patients
(93%) consisted of tacrolimus starting at 0.03 mg/
kg/day in a continuous i.v. infusion or 0.12 mg/kg
orally twice a day with dosage adjustment to maintain
blood levels between 5 and 20 ng/mL, and mycophe-
nolate mofetil (MMF) at 15-30 mg/kg every 6-12
hours either orally or i.v., as described previously
[19]. Tacrolimus was started either on the first day of
the conditioning regimen or day –1 pretransplanta-
tion, and MMF was started on day 11 posttransplan-
tation. Tacrolimus and MMF doses were tapered
in patients with # grade II aGVHD on day 130 for
malignant disease and on day 1180 for nonmalignant
disease [19]. Acute GVHD and cGHVD were graded
according to the Seattle criteria [20]. The 8 patients
who received unrelated PBSCs also received metho-
trexate (MTX) 15 mg/m2 i.v. on day 11, followed by
MTX 10 mg/m2 via slow i.v. push on days 13, 16,
and 111. Six patients who did not receive tacroli-
mus/MMF received cyclosporine (CsA) 1.5 mg/kg
i.v. from day -3 to day -5, along with MTX as described
above.
Infection Prophylaxis and Supportive Care
All patients were hospitalized in protective
isolation, defined as a single hospital room with
a high-efficiency particulate air filtration system and
reverse-isolation requiring strict hand sanitization
and mask use by staff for patients undergoing unre-
lated hematopoietic SCT. All patients received sargra-
mostim 250 mg/m2/day i.v. from day 0 until the white
blood cell count reached$300/mm3 for 2 days, fol-
lowed by filgrastim 10 mg/kg/day i.v. or s.c. until an
absolute neutrophil count (ANC) of$2500/mm3 was
achieved for 3 days, as described previously [21]. Her-
pes simplex virus (HSV) prophylaxis consisted of acy-
clovir 250 mg/m2 i.v. every 8 hours from day -5 until
the development of engraftment and# grade II muco-
sitis. Pneumocystis carinii prophylaxis consisted of
trimethoprim/sulfamethoxazole until day -2 and then
3 times weekly after myeloid engraftment. Patients
unable to tolerate trimethoprim/sulfamethoxazole
received i.v. pentamidine prophylaxis every 2 weeks.
Fungal prophylaxis consisted of liposomal amphoteri-
cin B 3 mg/kg/day i.v. from day 0 through day1100, as
described previously [22]. CMV prophylaxis wasadministered as described previously [23]. In brief,
patients at risk of acquiring CMV infection (ie,
a CMV-positive donor and/or recipient) after achiev-
ing an ANC.750/mm3 after allo-SCT received
foscarnet 90 mg/kg every other day, alternating with
ganciclovir 5 mg/kg every other day up to day 1100.
Systemic Viral Infections
CMV Infection and CMV Disease
CMV infection was defined as isolation of the
CMV virus or detection of viral nucleic acid in any
body fluid or tissue specimen. CMV systemic disease
was defined as the isolation of the CMV virus or detec-
tion of nucleic acid in any body fluid or tissue specimen
along with evidence of end-organ disease. Low risk for
CMV infection was defined as a CMV IgG-negative
donor and recipient; intermediate risk, as CMV
IgG-positive donor and CMV IgG-negative recipient;
and high risk, as CMV IgG-positive donor and recip-
ient or CMV IgG-positive recipient and CMV IgG-
negative donor.[24]
ADV Colonization and Infection
Recovery of ADV from stool culture was defined as
colonization. Patients who were culture- or polymer-
ase chain reaction (PCR)-positive for ADV with corre-
sponding clinical signs and symptoms were considered
to have ADV infection involving those site(s). Dissem-
inated ADV disease was defined as clinical evidence of
ADV infection involving 2 or more organ sites.
Other Viral Infections
BK/JC virus infection was defined as hemorrhagic
cystitis with a positive urine PCR. Human herpes
virus-6 (HHV-6) infection was defined as a positive
PCR from blood and/or cerebrospinal fluid. Upper
respiratory illness was defined as the acute onset of
any rhinorrhea, sinusitis, pharyngitis, or cough with
no clinical or radiologic evidence of lower respiratory
tract involvement and/or hypoxia, combined with
detection of the virus in upper respiratory secretions.
Lower respiratory illness was defined as clinical signs
and symptoms of lower respiratory involvement with
radiologic evidence of new pulmonary infiltrates with
or without hypoxia associated with detection of
the virus in nasal washings or broncoalveolar lavage
specimens [25].
Invasive Fungal Infections
IFIs were divided into candidemia, invasive asper-
gillosis, and other fungi. Invasive aspergillosis was de-
fined as possible (based on clinical signs and symptoms
plus a compatible thoracic computed tomography scan
or X-ray), probable (based on clinical signs and symp-
toms, compatible X-ray findings, plus a positive
1590 Biol Blood Marrow Transplant 15:1587-1595, 2009P. Satwani et al.respiratory tract culture for Aspergillus spp or positive
galactomannan assay), and definite (based on positive
histology for an invasive mold infection by Aspergillus)
infections. Candida infection was defined as a positive
fungal blood or urine culture or evidence of infection
in any organ system on radiographic evaluation or
proven by biopsy.Statistical Analysis
The c2 and t-tests were used to compare the char-
acteristics of the 2 groups with respect to categorical
and continuous variables, respectively. Continuous
variables were categorized when not normally distrib-
uted. Univariate and multivariate Cox regression
models were used to evaluate the association of differ-
ent risk factors for posttransplantation SVIs and IFIs.
The endpoint was time to diagnosis of SVIs and IFIs
separately. Patients were censored at relapse, death,
subsequent transplantation, or end of follow-up. For
patients who received more than 1 Bu-based condi-
tioning regimen during the specified time period,
only the first transplantation was evaluated. One
patient whose exact date of death was unknown was
censored at the date of last contact. In patients with
multiple infectious outcomes posttransplantation,
only the first incident that met one or both of the fore-
going definitions was included in the analysis. Time-
dependent variables, such as GVHD, were considered
potential risk factors only if they occurred before infec-
tion was diagnosed. Assumptions for proportional
hazards over time were checked for each model used.
Kaplan-Meier statistics and log-rank tests were used
to compare time to infection and survival between
groups. All reported P values are 2-sided and use
a significance level of .05. All statistical calculations
were performed using SAS 9.1 (SAS Institute, Cary,
NC). The multivariate model controlled for recipient
age, sex, diagnosis, conditioning type, stem cell source,
donor type, GVHD, and risk.RESULTS
Patients and Demographic Data
A total of 86 patients (52 males, 34 females; median
age, 7.5 years) received a Bu-based conditioning regi-
men during the study period. One patient who died
of progressive disease on day 11 was deemed
ineligible for analysis. The RIC arm comprised 53
patients, 39 of whom (74%) underwent transplantation
for a malignant condition (AML, n513; neuroblas-
toma, n59; Hodgkin lymphoma [HL], n58; chronic
myelogenous leukemia [CML], n54; non-Hodgkin
lymphoma, n54; and biphenotypic leukemia, n51)
and 14 of whom (26%) underwent transplantation
for a nonmalignant condition (sickle cell disease,n57; myelodysplastic syndrome [MDS], n52; thalas-
semia, n52; severe aplastic anemia [SAA], n52; and
scleroderma, n51). Of the 33 patients in the MAC
arm, 21 (64%) underwent transplantation for a malig-
nant condition (AML, n518; ALL, n51; undifferenti-
ated leukemia, n51; and neuroblastoma, n51) and 12
(36%) underwent transplantation for a nonmalignant
condition (sickle cell disease, n56; thalassemia, n52;
and hemophagocytic lymphohistiocytosis, n54) (Ta-
ble 1). The patients in the RIC and MAC arms had
similar performance status (95.3161.6 vs 93.861.8;
P5not significant).
Donor Sources
The donor sources in the RIC arm included UCB
in 28, PBSCs in 20 (14 related and 6 unrelated), and
BM in 5 (4 related and 1 unrelated). In the MAC
arm, the donor source was UCB in 18, PBSCs in 7
(4 related and 3 unrelated), and BM in 8 (7 related
and 1 unrelated).
Engraftment
The median time to neutrophil and platelet
engraftment was 17 days and 30 days, respectively in
the RIC arm and 14 days and 44 days, respectively,
in the MAC arm.
GVHD
The probability of developing aGVHD grade
II-IV was 29.1% (95% confidence interval [CI]5
16.7%-41.6%) in the RIC arm versus 40.3% (95%
CI523.9%-56.6%) in the MAC arm (P5.23 [not sig-
nificant]). The probability of developing cGVHD
was 28.9% (95% CI514.7%-43.0%) in the RIC arm
versus 28.4% (95% CI510.5%-46.3%) in the MAC
arm (P5.73 [not significant]).
Infections
SVIs
A total of 50 patients developed an SVI (RIC,
n529; MAC, n521) a median of 37 days (range,
10-449 days) after allo-SCT. In the RIC arm, the me-
dian time to onset of SVI was 70 days (range, 10-252
days), and the infectious organisms identified included
HSV (n53), CMV (n54), ADV (n54), respiratory
syncytial virus (RSV; n54), polyomavirus (n56), para-
influenza (n53), rotavirus (n52), varicella zoster virus
(VZV; n51), and calicivirus (n51). In the MAC arm,
the median time to onset of SVI was 33 days (range,
11-449 days), and the following viral organisms were
identified: polyomavirus (n58), CMV (n55), RSV
(n53), HSV (n52), parainfluenza (n51), HHV-6
(n51), rotavirus (n51), and ADV (n51). The overall
probability of developing an SVI was 58%. This prob-
ability did not differ significantly by conditioning
Table 1. Demographic and Clinical Characteristics
Characteristic
RIC Arm,
n (%)
MAC Arm,
n (%)
Total,
n (%) P
Patients 53 (62) 33 (38) 86 (100)
Sex
Male 33 (62) 19 (58) 52 (40)
.67Female 20 (38) 14 (42) 34 (60)
Age >7.5 years 26 (49) 17 (52) 43 (50) .82
Ethnicity
White 19 (36) 9 (27) 28 (33)
.334
Black 10 (19) 4 (12) 14 (16)
Hispanic 15 (28) 9 (27) 24 (28)
Other 9 (17) 11 (34) 20 (23)
Diagnosis
Malignant 39 (74) 21 (64) 60 (70)
.33Nonmalignant 14 (26) 12 (36) 26 (30)
Risk status
Poor risk 10 (19) 7 (21) 17 (20) .79
Average isk 43 (81) 26 (79) 69 (80)
Previous transplantation 19 (36) 0 (0) 19 (22) < .01
Stem cell source
PBSCs/BM 25 (47) 15 (45) 40 (47) .88
UCB 28 (53) 18 (55) 46 (53)
Matched related donor 16 (30) 11 (33) 27 (31) .76
CMV risk group
Low 17 (32) 6 (19) 23 (27)
.30
Intermediate 13 (25) 7 (22) 20 (24)
High 23 (43) 19 (59) 42 (49)
Hematopoietic recovery
ANC recovery <17 days 21 (49) 26 (64) 47 (55) .19
Platelet engraftment <32 days 8 (15) 5 (15) 13 (15) .99
GVHD status
Acute grade II-IV 16 (30) 13 (39) 29 (34) .38
Chronic 12 (23) 6 (18) 18 (21) .62
RIC indicates reduced intensity conditioning; MAC, myeloablative con-
ditioning; PBSCs, peripheral blood stem cells; BM, bone marrow;
UCB, umbilical cord blood; CMV, cytomegalovirus; ANC, absolute neu-
trophil count; GVHD, graft-versus-host disease.
Table 2. Multivariate Analysis of the Risk Factors for SVIs and
IFIs
SVIs IFIs
Risk Factor HR (95% CI) P HR (95% CI) P
Regimen
RIC 1.00 (reference) 1.00 (reference)
MA 1.28 (0.67-2.42) .46 0.12 (0.02-0.77) .03
CMV risk group
Low 1.00 (reference) 1.00 (reference)
Intermediate 1.15 (0.44-3.02) .79 7.25 (0.75-69.73) .07
High 2.83 (1.14-6.98) .03 26.73 (3.39-210.78) < .01
GVHD
Acute grade 0-1 1.00 (reference) 1.00 (reference)
Acute grade II-IV 1.63 (0.87-3.04) .13 2.25 (0.46-10.97) .31
Any chronic 0.89 (0.43-1.85) .75 0.76 (0.18-3.20) .71
Donor type
Matched related 1.00 (reference) 1.00 (reference)
Alternative donor 1.53 (0.70-3.35) .69 0.77 (0.13-4.57) .78
Age
#7.5 years 1.00 (reference) 1.00 (reference)
> 7.5 years 1.05 (0.99-1.11) .11 1.33 (1.13-1.56) < .01
Sex
Female 1.00 (reference) 1.00 (reference)
Male 1.05 (0.56-1.97) .90 0.72 (0.16-3.20) .67
Stem cell source
PBSCs/BM 1.00 (reference) 1.00 (reference)
UCB 0.86 (0.36-2.01) .72 6.26 (0.90-43.58) .06
Risk
Average 1.00 (reference) 1.00 (reference)
Poor 0.89 (0.38-2.07) .78 6.54 (1.14-37.36) .03
RIC indicates reduced intensity conditioning; SVIs, systemic viral infec-
tions; IFIs, invasive fungal infections; MAC, myeloablative conditioning;
PBSCs, peripheral blood stem cells; BM, bone marrow; UCB, umbilical
cord blood; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
Biol Blood Marrow Transplant 15:1587-1595, 2009 1591Viral and Fungal Infections following RIC allo-SCTintensity (P5.44) (Figure 1). In both univariate and
multivariate analyses, the only statistically significant
risk factor for SVI was CMV risk; subjects who were
seropositive and/or had a seropositive donor had
nearly 3 times the risk of seronegative subjects withFigure 1. Kaplan-Meier probability of developing an SVI in children in
the RIC arm versus those in the MAC arm.a seronegative donor (hazard ratio [HR]52.9; 95%
CI51.2-7.2; P5.02) (Table 2). Rabbit ATG and alem-
tuzumab were not associated with a significant increase
in SVIs in the univariate and multivariate analyses.
IFIs
A total of 13 patients developed an IFI (RIC arm,
n510; MAC arm, n53), occurring a median of 160
days (range, 8-630 days) after allo-SCT. In the RIC
arm, the median time to onset of IFI was 135 days
(range, 8-630 days), and the species associated with
infection were Candida spp (n57), Aspergillus spp
(n52), and mucor (n51). In the MAC arm, the median
time to onset of infection after allo-SCT was 167 days
(range, 41-260 days). Of the 3 infections in this group,
2 resulted from Candida spp and 1 frin Scedosporium
spp. Most (62%) of the fungal infections occurred be-
fore day 1180. The overall probability of developing
an IFI was 15%. This probability did not differ
significantly between the RIC and MAC arms
(P5.24) (Figure 2). In univariate analysis, only age
was significantly related to IFI; children age\7.5 years
appeared to have a lower risk than older children
(HR50.2; 95% CI50.04-0.74; P5.02). In a multivari-
ate Cox regression model, the following were identi-
fied as independent risk factors for IFI: older age
(HR51.3; 95% CI51.1-1.6; P \ .01), poor risk
Figure 2. Kaplan-Meier probability of developing an IFI in children in
the RIC arm versus those in the MAC arm.
Table 3. Multivariate Analysis of Risk Factor for Mortality
Risk Factor HR (95% CI) P
Regimen
RIC 1.00 (reference)
MAC 1.12 (0.40-3.57) .75
CMV risk group
Low 1.00 (reference)
Intermediate 0.17 (0.04-0.98) .05
High 0.80 (0.29-2.32) .69
GVHD
Acute grade 0-1 1.00 (reference)
Acute grade II-IV 1.93 (0.76-4.95) .17
Any chronic 0.60 (0.18-2.02) .41
Diagnoses
Nonmalignant 1.00 (reference)
Malignant 2.79 (0.73-0.70) .13
Donor type
Matched related 1.00 (reference)
Alternative donor 0.98 (0.28-3.48) .98
Age
#7.5 years 1.00 (reference)
>7.5 years 1.03 (0.95-1.12) .53
Sex
Female 1.00 (reference)
Male 0.68 (0.29-1.56) .36
Stem cell source
PBSCs/BM 1.00 (reference)
UCB 3.23 (1.00-10.42) .05
Risk
Average 1.00 (reference)
Poor 3.53 (1.31-9.51) .01
Previous transplantation
No 1.0 (reference)
Yes 4.53 (1.23-16.77) .02
IFIs
No 1.0 (reference)
Yes 4.66 (1.52-14.35) < .01
SVIs
No 1.0 (reference)
Yes 0.65 (0.27-1.53) .31
RIC indicates reduced intensity conditioning; SVIs, systemic viral infec-
tions; IFIs, invasive fungal infections; MAC, myeloablative conditioning;
PBSCs, peripheral blood stem cells; BM, bone marrow; UCB, umbilical
cord blood; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
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positive recipient (high vs low CMV risk group:
HR526.7; 95% CI53.4-210.8; P \ .01) (Table 2).
In addition, in the multivariate model, patients in the
MAC arm appeared to have a significantly lower risk
of IFI than those in the RIC arm (HR50.1; 95%
CI50.02-0.8; P5.03). Rabbit ATG and alemtuzumab
were not associated with a significant increase in IFI in
the univariate and multivariate analyses.
Survival/Mortality
Some 70% of the patients in the RIC arm and 61%
of those in the MAC arm were alive at the end of
follow-up, with a median survival of 812 days (range,
15-2328 days) and 429 days (range, 39-2808 days),
respectively. The 2 groups did not differ significantlyFigure 3. Kaplan-Meier probability for OS in children in the RIC arm
versus those in the MAC arm.in terms of overall survival (OS) (P5.4) (Figure 3).
Factors significantly associated with mortality in the
multivariate model included poor risk (HR53.5;
95% CI51.3- 9.5; P5.01), IFI (HR52.6; 95%
CI51.1-6.0; P5.02) and previous transplantation
(HR54.5; 95% CI51.2-16.7; P5.02) (Table 3). The
multivariate model controlled for conditioning type,
diagnosis, age, sex, stem cell source, CMV risk group,
and GVHD. Having an SVI was not associated with
poor survival (P5.87), but having an IFI significantly
reduced OS (P \ .01). This difference persisted
when the analysis was stratified by conditioning type.
Overall infection-related mortality was only 1.1%
(1/86) for SVIs and 2.3% (2/86) for IFIs. The only
death likely related to an SVI was secondary to RSV
pneumonia in a patient with induction failure AML
on day 1144 after an HLA-matched sibling RIC
allo-SCT; during administration of aerosolized riba-
varin, the patient relapsed and died of AML. Two
deaths were related to IFI. One patient had SAA and
grade III aGVHD and subsequently developed
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phoma and extensive cGVHD, and later died of Asper-
gillus fumigatus.DISCUSSION
Regimen-related mortality after MAC allo-SCT in
pediatric recipients can be as high as 20%-40%
[26-28]. In our experience with RIC allo-SCT in pedi-
atric recipients, the day 1100 nonrelapse mortality
(NRM) was only 1.3% [29]. This decrease in day
1100 NRM may result in part from the decreased
risk of early life-threatening infections. However,
these 2 different conditioning regimens (RIC and
MAC) have not been compared with respect to the
rates of SVIs and IFIs in pediatric allo-SCT recipients.
Here, we report the incidence of SVIs and IFIs in chil-
dren and adolescents who received a Bu-based MAC or
RIC regimen when undergoing allo-SCT. We did not
include patients who received TBI-based conditioning
because (1) the most common indication for a TBI-
based conditioning regimen is ALL, and we have not
performed any RIC allo-SCT for ALL, and (2) we
have not used TBI as a part of the conditioning regi-
men for RIC allo-SCT. The literature on the use of
RIC in children and adults with ALL is limited; how-
ever, a recent study by Kennedy-Nasser et al. [30] of
children with ALL who received a TBI-containing
MAC regimen found a 16% incidence of CMV reacti-
vation (14/83), a 19% incidence of adenovirus reacti-
vation (16/83), and a 4.8% incidence of IFIs (4/83)
[30]. In our study, the incidence of CMV reactivation
was 15%, that of adenovirus reactivation was 3%,
and that of IFI was 9.0% in the MAC arm.
We found no significant difference between pediat-
ric RIC allo-SCT and MAC allo-SCT recipients in
terms of incidence of SVI or OS. However, the patients
in the MAC arm appeared to have a significantly lower
risk of IFI. These results are not surprising given that
38% of the patients in the RIC arm received an MAC
autologous transplantation before undergoing a RIC
allo-SCT; their underlying risk of infection may have
initially been greater because of previous chemother-
apy. In addition, while several studies have reported
a similar risk of IFI in RIC allo-SCT and MAC allo-
SCT recipients, our findings are more consistent with
those of Fukuda et al., who found a trend toward
a higher risk of invasive aspergillosis among nonmye-
loablative (NMA) recipients [18, 31, 32]. In that study,
the cumulative incidence rates of proven or probable
IFI, invasive mold infections, invasive aspergillosis,
and invasive candidiasis during the first year after
allo-SCT with NMA conditioning were 19%, 15%,
14%, and 5%, respectively, and 39% deaths were re-
lated to a mold infection. In contrast, in our study
only 2 deaths (2.3%) were related to IFI.Despite the lower risk of IFI in the MAC arm, the
19% overall risk of developing IFI in the RIC arm was
not significantly different from the 17% incidence
reported in a recent study of adult RIC allo-SCT
recipients [33]. A possible reason for the higher inci-
dence of IFIs in RIC allo-SCT recipients may be
secondary to the need for prolonged immunosuppres-
sion and greater risk of graft failure in RIC allo-SCT
recipients. The use of alemtuzumab in immunosup-
pressive conditioning has been associated with delayed
immune reconstitution.
Our failure to detect a significant difference in inci-
dence of SVIs is consistent with the results of other
studies. In one matched case-controlled study of 168
adult allo-SCT recipients, the 1-year incidence of
CMV disease was similar in those receiving RIC and
those receiving MAC [10]. Likewise, a study by Schete-
lig et al. [34] comparing a Bu-based RIC allo-SCT reg-
imen to MAC allo-SCT conditioning found no
significant difference in the incidence of CMV infection
[34].
The risk factors for SVIs and IFIs identified in this
study, including CMV seropositivity and patient age,
are similar to those reported previously, with the major
exception of GVHD [35, 36]. Our failure to detect an
association between infection and GVHD in the pres-
ent study may be from the lower incidence of GVHD
in this population than has been reported previously
in RIC allo-SCT recipients, and might be linked to
the different GVHD prophylaxis regimens used in
our cohort [37].
One potential concern following RIC allo-SCT is
the possible increase in the incidence of EBV reactiva-
tion and lymphoproliferative disorder, which appears
to be higher in patients receiving ATG as a part of
the allo-SCT conditioning regimen [38]. In our series
of 86 patients, 44 received ATG (MAC arm, n521;
RIC arm, n523) and 16 received alemtuzumab. None
of the children experienced EBV reactivation, and
only 1 child had EBV-negative lymphoproliferative
disorder. In addition, alemtuzumab has been associated
with a significant risk of CMV reactivation. Chakra-
barti et al. [39] found a 50% incidence of CMV reacti-
vation in adult patients receiving alemtuzumab as a part
of RIC allo-SCT, but a 84.8% probability of develop-
ing a CMV reactivation in those patients at intermedi-
ate and high risk for CMV [39]. Similarly in a study by
Shenoy et al. [40] of children receiving Flu, Mel, and
alemtuzumab RIC, 6 of 7 CMV-positive recipients
and 1 CMV-negative recipient reactivated CMV. In
our study, 36 of 53 children (68%) in the RIC arm
were at intermediate or high risk for CMV infection,
but only 4 of these children developed CMV reactiva-
tion, including 2 of 16 children who received alemtuzu-
mab. This low incidence of CMV reactivation in our
patient population could be due to the aggressive
CMV prophylaxis instituted at our center [23]. We
1594 Biol Blood Marrow Transplant 15:1587-1595, 2009P. Satwani et al.also found no significant difference in the incidence of
SVIs and IFIs in children who received ATG and those
who received alemtuzumab.
The major limitation of this retrospective study is
the small sample size of both groups. Our proportional
hazards assumptions were not met, most likely due to
the small sample size. When we ran these same analy-
ses using a simple logistic regression model, CMV
high-risk status was the only significant risk factor
for SVI. CMV high-risk status, older age, and malig-
nant condition remained significant risk factors for
IFI. In addition, CMV intermediate risk, malignant
disease, poor risk disease status, and IFI remained sig-
nificant risk factors for mortality. These results are
consistent with those from the Cox regression models.
Because the subjects were heterogeneous in terms of
underlying disease and donor source, these prelimi-
nary analyses should be replicated in additional studies
of children with more homogenous diagnoses and cell
sources.
Despite these limitations, however, we believe that
our central conclusions are valid. The fact that this
study was conducted at a single institution ensures
consistent policies and protocols in terms of prophy-
laxis, isolation precautions, and diagnosis of infection.
Furthemore, the fact that all conditioning regimens
were busulfan-based allows for greater comparability
between subjects in the 2 groups.
When assessing the risk of SVIs and IFIs in children
undergoing allo-SCT, we need to consider various
other factors beyond the conditioning regimen. Com-
pared with heavily pretreated patients, patients who
undergo allo-SCT for nonmalignant disease (other
than immunodeficiency) have a lower risk of infection
following allo-SCT due to an intact immune system, ab-
sence of chemotherapy-related thymic injury, and lack
of significant end organ damage. Patients with ex vivo
or in vivo T cell depletion related to alemtuzumab are
at risk for SVIs due to delayed immune reconstitution.
Donor source also may have an impact on the risk of
SVIs and IFIs. Compared to with children undergoing
allo-SCT with UCB (delayed immune reconstitution)
or an unrelated donor (increased risk of GVHD), chil-
dren undergoing HLA-matched sibling allo-SCT have
a lower risk of GVHD and relatively faster immune
reconstitution, which may lead to a decreased incidence
of SVIs and IFIs. One of the most critical risk factors for
SVIs and IFIs is GVHD and its treatment with steroids
and other immunosuppressive therapy. In our statistical
analysis, although we controlled for all of these risk
factors, we were unable to demonstrate the individual
impacts of these factors on the risk of SVIs and IFIs,
likely due to the small number of subjects.
In summary, our findings indicate that in children,
RIC allo-SCT is not associated with a higher risk of
SVIs compared with MAC allo-SCT, but might be
associated with a greater incidence of IFIs. Moreover,due to the availability of sophisticated monitoring and
newer antibiotics and other therapeutic strategies,
both SVIs and IFIs are not associated with mortality
in pediatric allo-SCT recipients.ACKNOWLEDGMENTS
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